GenMark ePlex Respiratory Pathogen Panel 2 receives EUA

written by CAP TODAY
October 9, 2020

Oct. 9, 2020—GenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2. The test provides results in less than two hours for more than 20 viruses and bacteria that cause respiratory infections, including COVID-19, flu, bronchitis, and the common cold.

“RP2 provides our hospital with incredible peace of mind and value in helping us serve our patients, which includes a large geriatric patient population that is at increased risk for COVID-19. Since implementing RP2, we went from a seven- to 10-day turnaround time, to getting results in under two hours,” Teri Robertson, BSMT, laboratory director at Graham Regional Medical Center, in Graham, Tex., said in a GenMark press release.

The ePlex RP2 Panel is designed for use with the company’s moderately complex ePlex system, along with the CE-marked and FDA-cleared ePlex RP panel and blood culture identification panels (Gram-positive, Gram-negative, and fungal pathogens).